Regeneron's Schleifer, Yancopoulos set their company's ambitions sky high with $1.4B on the table in performance awards
One of the true success stories in biopharma, New York’s Regeneron has built a $51 billion market cap under the watchful eyes of co-founders and 32-year veterans Len Schleifer and George Yancopoulos. That success has made both men wealthy, even as Regeneron’s investor returns have flagged in recent years.
Regeneron’s ambitions are still sky high moving ahead — and just how much the company can capitalize on that vision could spell enormous paydays for its founders.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.